OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 12 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period).
Gout in Older Adults
Submission Deadline: December 30, 2021 (Open) Submit Now
Takahiko Nakagawa, MD, PhD
Professor, Department of Nephrology, Rakuwakai Otowa Hospital, 2 Otowa-Chinji-cho, Yamashina-ku, Kyoto, Japan;
Department of Stem Cell Biology and Regenerative Medicine, Shiga University of Medical Science, Shiga, Japan
Research Interests: Hypertension; diabetes; insulin resistance; gout; sugar-induced metabolic dysfunction; hyperuricaemia; endothelial function; endothelial dysfunction; acute kidney injury; uric acid
About This Topic
Gout is one of the most common inflammatory arthritis in world wide. Accumulating evidence have witnessed that gout is strongly associated with hypertension, kidney disease, obesity and metabolic syndrome. Interestingly, this common arthritis is often complicated with several types of cancer. Thus, current life style could be a cause for the development of gout, and perhaps a common mechanism underlying these disorders might exist. A lowering uric acid with xanthine oxidase inhibitors and/or uricosuric drugs is the gold standard for treating gout. However, it likely fails to eliminate this common disease in the modern society so that a better understanding for the pathophysiology of gout and uric acid would be required. In this special issue, we would like to update the understanding of gout and uric acid to step further for improving the quality of life in patients with gout.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.